Skip to content
  • Pipeline
    • SurVaxM
  • Clinical Trials
  • About
    • Leadership Team
  • News
  • Contact
Menu
  • Pipeline
    • SurVaxM
  • Clinical Trials
  • About
    • Leadership Team
  • News
  • Contact
Pipeline
SurVaxM
Clinical Trials
About
Leadership Team
News
Contact
Read more about the article George Washington University Researchers presenting at 2019 MGFA Scientific Session, AANEM Annual Meeting

George Washington University Researchers presenting at 2019 MGFA Scientific Session, AANEM Annual Meeting

  • Post author:web-designer
  • Post published:October 7, 2019
  • Post category:Uncategorized

Linda Kusner, PhD will present new data utilizing MV2C2 antibodies in Myasthenia Gravis. “Survivin is a negative regulator of apoptosis in myasthenia gravis: a human and animal model study” (October 16,…

Continue ReadingGeorge Washington University Researchers presenting at 2019 MGFA Scientific Session, AANEM Annual Meeting

Recent Posts

  • MimiVax Announces Positive Final Data from the Phase IIa Study of SurVaxM for Newly Diagnosed Glioblastoma Published Today in the Journal of Clinical Oncology
  • Phase 2a Trial of SurVaxM Plus Temozolomide for Newly Diagnosed Glioblastoma
  • Roswell Park Opens Phase 2B Randomized Clinical Trial of Promising Brain Cancer Immunotherapy
  • MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma
  • MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients.

Recent Comments

    Archives

    • December 2022
    • November 2022
    • February 2022
    • November 2021
    • May 2020
    • November 2019
    • October 2019
    • May 2019
    • March 2018
    • August 2017
    • July 2016
    • September 2015
    • April 2015

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    MimiVax, LLC

    info@mimivax.com

    Elm & Carlton Streets
    Buffalo, NY 14263

    Back to top
    Twitter Linkedin Youtube